According to CNBC, shares of Wegovy-maker Novo Nordisk rose 6% after approval of a GLP-1 pill, signaling a strong positive price reaction to the regulatory catalyst, source: CNBC. CNBC did not provide additional details in the tweet or any direct implications for the crypto market, source: CNBC.

According to @CNBC, Novo Nordisk shares fell about 10% after its Alzheimer’s drug trial failed to hit a key target, triggering an immediate downside reaction in the stock (source: CNBC). @CNBC also indicates the report did not cite any direct impact on cryptocurrency markets, leaving digital assets unaffected by this headline based on the information provided (source: CNBC).

According to @StockMKTNewz, Novo Nordisk (NVO) lowered its direct-to-consumer weight-loss drug price for existing cash-paying patients to $349 per month from $499, a $150 (approximately 30 percent) cut, source: @StockMKTNewz citing CNBC. This change translates to roughly $1,800 less in annual out-of-pocket costs per patient at the stated price points, source: @StockMKTNewz citing CNBC. No direct crypto market impact or specific product names were disclosed by the source, which focused solely on the pricing adjustment, source: @StockMKTNewz citing CNBC.